PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
HQL vs. IYH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between HQL and IYH is 0.63, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.6

Performance

HQL vs. IYH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tekla Life Sciences Investors (HQL) and iShares U.S. Healthcare ETF (IYH). The values are adjusted to include any dividend payments, if applicable.

-12.00%-10.00%-8.00%-6.00%-4.00%-2.00%0.00%2.00%SeptemberOctoberNovemberDecember2025February
-3.70%
-6.16%
HQL
IYH

Key characteristics

Sharpe Ratio

HQL:

0.91

IYH:

0.15

Sortino Ratio

HQL:

1.31

IYH:

0.29

Omega Ratio

HQL:

1.17

IYH:

1.03

Calmar Ratio

HQL:

0.57

IYH:

0.14

Martin Ratio

HQL:

3.10

IYH:

0.35

Ulcer Index

HQL:

5.00%

IYH:

4.95%

Daily Std Dev

HQL:

17.06%

IYH:

11.53%

Max Drawdown

HQL:

-61.70%

IYH:

-43.12%

Current Drawdown

HQL:

-10.86%

IYH:

-7.78%

Returns By Period

In the year-to-date period, HQL achieves a 8.00% return, which is significantly higher than IYH's 4.32% return. Over the past 10 years, HQL has underperformed IYH with an annualized return of 2.84%, while IYH has yielded a comparatively higher 8.60% annualized return.


HQL

YTD

8.00%

1M

5.12%

6M

-3.70%

1Y

14.47%

5Y*

5.16%

10Y*

2.84%

IYH

YTD

4.32%

1M

2.50%

6M

-6.15%

1Y

0.72%

5Y*

8.02%

10Y*

8.60%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

HQL vs. IYH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HQL
The Risk-Adjusted Performance Rank of HQL is 6969
Overall Rank
The Sharpe Ratio Rank of HQL is 7474
Sharpe Ratio Rank
The Sortino Ratio Rank of HQL is 6565
Sortino Ratio Rank
The Omega Ratio Rank of HQL is 6464
Omega Ratio Rank
The Calmar Ratio Rank of HQL is 6868
Calmar Ratio Rank
The Martin Ratio Rank of HQL is 7272
Martin Ratio Rank

IYH
The Risk-Adjusted Performance Rank of IYH is 99
Overall Rank
The Sharpe Ratio Rank of IYH is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of IYH is 88
Sortino Ratio Rank
The Omega Ratio Rank of IYH is 88
Omega Ratio Rank
The Calmar Ratio Rank of IYH is 1010
Calmar Ratio Rank
The Martin Ratio Rank of IYH is 99
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HQL vs. IYH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Tekla Life Sciences Investors (HQL) and iShares U.S. Healthcare ETF (IYH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for HQL, currently valued at 0.91, compared to the broader market-2.000.002.004.000.910.15
The chart of Sortino ratio for HQL, currently valued at 1.31, compared to the broader market-6.00-4.00-2.000.002.004.006.001.310.29
The chart of Omega ratio for HQL, currently valued at 1.17, compared to the broader market0.501.001.502.001.171.03
The chart of Calmar ratio for HQL, currently valued at 0.57, compared to the broader market0.002.004.006.000.570.14
The chart of Martin ratio for HQL, currently valued at 3.10, compared to the broader market0.0010.0020.0030.003.100.35
HQL
IYH

The current HQL Sharpe Ratio is 0.91, which is higher than the IYH Sharpe Ratio of 0.15. The chart below compares the historical Sharpe Ratios of HQL and IYH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.003.50SeptemberOctoberNovemberDecember2025February
0.91
0.15
HQL
IYH

Dividends

HQL vs. IYH - Dividend Comparison

HQL's dividend yield for the trailing twelve months is around 13.13%, more than IYH's 1.20% yield.


TTM20242023202220212020201920182017201620152014
HQL
Tekla Life Sciences Investors
13.13%14.18%9.44%9.57%8.79%7.90%8.03%10.72%8.25%12.18%11.84%7.11%
IYH
iShares U.S. Healthcare ETF
1.20%1.25%1.18%1.10%0.94%1.16%1.14%1.95%1.10%1.29%2.02%1.05%

Drawdowns

HQL vs. IYH - Drawdown Comparison

The maximum HQL drawdown since its inception was -61.70%, which is greater than IYH's maximum drawdown of -43.12%. Use the drawdown chart below to compare losses from any high point for HQL and IYH. For additional features, visit the drawdowns tool.


-15.00%-10.00%-5.00%0.00%SeptemberOctoberNovemberDecember2025February
-10.86%
-7.78%
HQL
IYH

Volatility

HQL vs. IYH - Volatility Comparison

Tekla Life Sciences Investors (HQL) has a higher volatility of 4.71% compared to iShares U.S. Healthcare ETF (IYH) at 4.07%. This indicates that HQL's price experiences larger fluctuations and is considered to be riskier than IYH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%SeptemberOctoberNovemberDecember2025February
4.71%
4.07%
HQL
IYH
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab